Abstract: A removable gas supply for a weapon simulator, wherein the gas system cycles the bolt or slide of the firearm to provide recoil, actuate a hammer/trigger mechanism and provide realism of the original weapon functions. The weapon simulator has a housing defining a piston chamber and a piston positioned in said chamber and connected to the bolt. The simulator also includes a valve chamber in the housing connected with said regulated gas supply and said bolt, and a recoil valve positioned in the valve chamber to control the release of gas from said regulated gas supply to said piston chamber to generate recoil in the weapon simulator.

Abstract: A bolt locking assembly for a weapon simulator, the weapon simulator having a bolt affixed to a firearm housing providing recoil to the user. The bolt is connected to a piston housed in a piston chamber inside the housing. A gas supply provides a compressed gas or fluid into the piston chamber to generate movement and recoil of the piston. After the weapon simulator has been fired a predetermined number of times, the bolt locking assembly will obstruct operation of the bolt and piston. The bolt locking assembly includes a lock actuator port engaging the piston chamber, a locking apparatus positioned within the housing proximate the bolt, and a lock channel between said lock actuator port and said locking arm, wherein the lock channel directs gas to said locking apparatus to actuate said locking apparatus and fix the bolt in place.

Abstract: A method of treating an animal with a single treatment device (1), including a primary (medical) treatment (8) and a secondary (marking) treatment (6), characterised in applying the secondary (marking) treatment with the device prior to applying the primary (medical) treatment with the same device.

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Abstract: The invention provides a method of screening for agents that promote or inhibit vasculogenesis or angiogenesis. The screening methods comprise culturing mesodermal stem cells, for example, allantoic cells; contacting the mesodermal stem cells with the agent to be screened; detecting endothelial cells or endothelial stem cells in the culture; and comparing the endothelial cells or endothelial cell precursors in the culture to be screened, with the endothelial cells or endothelial cell precursors in a control culture. An increase in endothelial cells or endothelial cell precursors in the culture to be screened indicates an agent that promotes vasculogenesis or angiogenesis. A decrease in endothelial cells or endothelial cell precursors in the culture to be screened indicates an agent that inhibits vasculogenesis or angiogenesis.